Zdrowie i gospodarka · 05/02/2020

FDA Announces Draft Guidance for Developing Drugs for Rare Mucopolysaccharidosis Type III (Sanfilippo Syndrome)

The FDA is releasing a draft guidance to streamline the development of treatments for Sanfilippo Syndrome, a rare genetic disorder, with the aim of improving clinical trial data quality and accelerating the approval of new treatments.